Biocept (BIOC) Reports Q1 Loss of $0.25/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Biocept Reports 2016 First Quarter Financial Results
May 12, 2016 4:06 PM EDTSAN DIEGO, May 12, 2016 /PRNewswire/ --Â Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the diagnosis and treatment of cancer, reports financial results for the quarter ended March 31, 2016, and provides an update on business progress.Â
"We are reporting a record 810 billable samples for the first quarter of 2016 and substantial progress on each of the... More
